93 results about "Protein neddylation" patented technology

Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.

A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.

Methods and compositions for the rapid and reversible destabilizing of specific proteins using cell-permeable, synthetic molecules are described. Stability-affecting proteins, e.g., derived from FKBP and DHFR proteins are fused to a protein of interest and the presence or absence of the ligand is used to modulate the stability of the fusion protein.

Therapeutic protein fusions comprising anti-HER2 antibody and MicB sequences are described along with methods for their production and use

The present invention provides polynucleotides and expression vectors containing a sequence encoding a soluble lysosomal enzyme and a sequence encoding Tat protein transduction domain (PTD), and the corresponding polypeptides. The present demonstrates the utility of these protein fusions in altering the bioavailability of proteins for use in treating genetic diseases or acquired diseases. The invention further provides cell expression systems, and methods of treating a genetic disease or cancer in a mammal using the polynucleotides, polypeptides, or expression system of the present invention.

A method is described for altering the properties such as the accumulation, the stability and/or integrity, the subcellular localisation, the post-translational modifications, the ability to get purified, and the phase partitioning behaviour of natural or recombinant target proteins expressed in a host organism. The method involves the co-expression of natural or recombinant proteins along with a specific binding partner that sequesters the target recombinant protein into a complex. The binding partner is supplied as a separate protein allowing formation of intermolecular complexes or is fused to the protein of interest, allowing the formation of intramolecular complexes. The binding partner can also be used to alter the subcellular localisation without modifying the sequence or structure of the target protein itself. This can be achieved by either incorporating appropriate targeting signals into the binding ligand, which are then linked to the target protein through complex formation, or complex formation itself may alter the subcellular localisation. The same strategy can be used to provide an affinity tag to facilitate protein purification. The principle of the invention is demonstrated by the coexpression of an unstable antibody and its cognate antigen.

The invention provides methods of determining the presence of a nuclear localization signal and/or the presence of a nuclear export signal in a protein of interest. The invention further provides chimeric nucleic acids and recombinant host cells for use in such methods. Additionally provided is a nucleic acid molecule encoding a modified LexA protein, wherein the modified LexA protein has no nuclear localization signal, as well as the modified LexA protein itself. In the nuclear import assay, if a protein of interest fused to a mLexA-Gal4AD hybrid contains a functional NLS, the fusion product will enter the yeast cell nucleus and activate the expression of reporter genes. In the nuclear export assay, if a protein of interest fused to a mLexA-SV40 NLS-Gal4AD hybrid contains a functional NES, the fusion product localized to the cell nucleus will exit into the cytoplasm, decreasing the reporter gene expression levels.

Disclosed are a polyacrylamide-based method of fabricating surface-bound peptide and protein arrays, the arrays themselves, and a method of using the arrays to detect biomolecules and to measure their concentration, binding affinity, and kinetics. Peptides, proteins, fusion proteins, protein complexes, nucleic acids, and the like, are labeled with an acrylic moiety and attached to acrylic-functionalized glass surfaces through a copolymerization with acrylic monomer. The specific attachment of GST-green fluorescent protein (GFP) fusion protein was more than 7-fold greater than the nonspecific attachment of non-acrylic labeled GST-GFP. Surface-attached GST-GFP (0.32 ng/mm²) was detectable by direct measurement of GFP fluorescence and this lower detection limit was reduced to 0.080 ng/mm² using indirect antibody-based detection. The polyacrylamide-based surface attachment strategy was also used to measure the kinetics of substrate phosphorylation by the kinase c-Src. The surface attachment strategy is applicable to the proteomics field and addresses denaturation and dehydration problems associated with protein microarray development.

The present invention relates to methods and compositions that can be employed to introduce toxins and nucleic acids into the cytoplasm or nucleus of a eukaryotic cell, particularly a cell of a higher vertebate. The invention particularly concerns the use of a fusion protein of streptavidin and protein A sequences to form a non-covalent complex of a toxin or nucleic acid and an antibody.

The invention provides a pharmaceutical formulation for manufacturing a clinical medicament for recombined human serum albumin/therapeutic protein fusion proteins for injection, which is universal, simple and extremely effective. The pharmaceutical formulation and a freeze-drying process include that a clinical therapeutic injecting injection is formed by using single effective formulation to prepare, freeze and dry different recombined human serum albumin fusion proteins. Frozen and dried injection is capable of decreasing the possibility of forming fractured dissociative human serum albumins, dissociative therapeutic protein fragments and fusion protein polymers. Products can be stored in a long period of time and are not easy to be decomposed or degenerated; the products have accurate dose, fine appearance, good stability and high safety and can greatly improve the safety of pharmacy. The pharmaceutical formulation and production process steps are simple and unique, high in quality and easy in industrialization, and pharmaceutics has the greatest advantages that no allergy or toxic and side effects are produced to human bodies and the like.

The invention discloses a nanometer molecular biosensor and a preparation method thereof. The biosensor is mainly characterized in that a molecular biosensor is self-assembled into a nanometer molecular biosensor by adopting nanowire protein, and compared with an unassembled molecular biosensor, the detection sensitivity is greatly improved. The preparation method adopts the protein fusion technology, and fuses nanowire protein with self-assembled function, special enzyme molecule used as a biology identification element and fluorescence protein used as a transducer element, therefore, functional protein with self-assembled nanowire, identification and transduction output signal functions simultaneously, and after the functional protein is expressed and purified, the functional protein is self-assembled into a nanometer molecular biosensor which can be used for inspecting object molecules in various clinical samples and environment samples. The invention simultaneously discloses an application of the nanometer molecular biosensor prepared by the preparation method in pesticide methyl parathion detection.